2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow RPL554 Suspension: new trials by email Literature Review of RPL554 Suspension trials Research Report on RPL554 Suspension
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD RPL554 Suspension, Placebo, Tiotropium/olodaterol (Respimat) - COPD | Phase 2 | Completed | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 79 | 2018-07-16 | 2019-10-10 |
| Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients RPL554 suspension, Placebo - COPD | Phase 2 | Completed | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 405 | 2017-06-01 | 2019-06-04 |
Pulmonary Disease, Chronic Obstructive (2)
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA (2)
United Kingdom (2) · Bulgaria (1) · Czechia (1) · Germany (1) · Poland (1) · Romania (1) · United States (1)
Dave Singh (1)